remove_red_eye 881 Views
#Cardiology #Internal Medicine #Pathology and Lab Medicine #Pharmacist #Rheumatology
Febuxostat was similar to allopurinol with respect to rates of adverse cardiovascular events in patients with gout and major cardiovascular coexisting conditions, according to the CARES trial published March 12, 2018 in the New England Journal of Medicine. However, all-cause mortality and cardiovascular mortality were higher with febuxostat.
Continue reading your article with a Emedinexus account..